NCT06664983
TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
progression-free survival
Timeframe: from the enrollment to disease progression or death from any cause, assessed up to 12 months
Arms and interventions
TPC chemotherapyActive comparator
NAB-paclitaxel; cisplatin or lobaplatin and capecitabine
Cadonilimab with TPC chemotherapyExperimental
cadonilimab plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin ; and capecitabine
Drugs: TPC chemotherapy, cadonilimab combined TPC chemotherapy
Sites
1 site in 1 country
- SunYat-senUGuangzhou, Guangdong, China